Netakimab
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control[2].
Product Specifications
CAS Number
1796570-08-5
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/netakimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Netakimab]
Molecular Weight
(145.74 kDa)
References & Citations
[1]Puig L, et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb) . 2021 Aug;11 (4) :1319-1332. |[2]Erdes S, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020 Jan-Feb;38 (1) :27-34. Epub 2019 Apr 16.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
